^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    NOUS-209

    i
    Associations
    News

    Trials

    Company:
    Nouscom
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients (NCT05078866)
    Phase 1/2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    11/10/2022
    Primary completion :
    07/31/2025
    Completion :
    07/31/2025
    BRAF • MSI • MLH1 • MSH6 • MSH2
    |
    BRAF mutation
    |
    NOUS-209
    Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors (KEYNOTE-E58) (NCT04041310)
    Phase 1/2
    Nouscom SRL
    Active, not recruiting
    Last update posted :
    11/20/2024
    Initiation :
    10/21/2019
    Primary completion :
    04/30/2025
    Completion :
    11/30/2026
    MSI
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • NOUS-209